Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Relinqing Granule + ciprofloxacin is a combination therapy used for the treatment of chronic prostatitis, particularly chronic bacterial prostatitis and inflammatory chronic pelvic pain syndrome. Relinqing Granule is a Traditional Chinese Medicine (TCM) preparation derived from the herb *Polygonum capitatum*, which possesses anti-inflammatory, anti-infective, and diuretic properties. Ciprofloxacin is a second-generation fluoroquinolone antibiotic that exerts its bactericidal effect by inhibiting DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, and repair. The combination is designed to provide a synergistic effect where ciprofloxacin addresses the underlying bacterial infection while Relinqing Granule alleviates clinical symptoms such as urinary frequency, urgency, and pelvic pain by reducing inflammation and promoting diuresis. This therapeutic approach is widely studied and applied in China to improve cure rates and reduce the recurrence of prostatic inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on relinqing granule + ciprofloxacin.